ArticleCureus2026
Definitive Radiation Therapy for Older Adults With Localized Prostate Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Individual health and life expectancy, rather than age, should drive management decisions for patients with prostate cancer. There is limited available data regarding treatment outcomes and tolerance for older adults where health status warranted treatment with curative intent. Herein, we report treatment outcomes for patients 80 years and older who received definitive radiation therapy (RT) for localized prostate cancer. Methods This retrospective study includes 41 patients who received RT for localized prostate cancer at the age of 80 years or older between 2004 and 2022. The median age was 83. Baseline details and outcomes, including treatment toxicity, symptom scores, biochemical recurrence (BR), distant metastases (DM), and overall survival (OS), were collected in a secure database and analyzed with Graphpad Prism (GraphPad Software, Boston, MA, USA) and R software (version 4.5; R Foundation for Statistical Computing, Vienna, Austria). Results No patients experienced adverse events that were Common Terminology Criteria for Adverse Events (CTCAE) grade 4 or higher. One patient (2.4%) experienced late CTCAE grade 3 proctitis, seven patients (17.1%) experienced acute CTCAE grade 2 genitourinary adverse events (GU AE), and five patients (12.2%) experienced late grade 2 GU AEs. Mean urinary symptom scores improved after RT (with the International Prostate Symptom Score (IPSS) decreasing from 12.1 pre-RT to 8.2 post-RT). The estimated four-year cumulative incidence of metastases was 6.7% (95% CI 0-16.1%). There were trends in outcomes based on risk group, but no statistically significant differences between intermediate risk cancer (IR) and high or very high-risk cancer (HR/VHR) regarding BF (15% vs. 20%, p=0.17), DM (0% vs. 10%, p=0.20), or OS (94% vs. 96%, p=0.38). Conclusions Definitive RT for patients 80 years or older was generally well tolerated and effective in this small cohort. These findings may indicate a favorable risk/benefit ratio for definitive prostate cancer treatment for select patients 80 years or older. Decision-making for prostate cancer treatment should involve a comprehensive approach, accounting for each individual patient's life expectancy and overall health rather than avoidance of treatment based simply on age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.